Nerve disruption with chemoimmunotherapy for advanced tongue cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests whether adding a nerve disruption in the tongue can help the standard pre-surgery combination of chemotherapy and immunotherapy work better for people with advanced tongue cancer. The goal is to improve treatment before removing the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of tongue cancer called squamous cell carcinoma that is locally advanced (not spread to other parts).
- Your treatment plan includes two rounds of chemotherapy and immunotherapy before surgery to remove the tongue cancer.
- You do not have any major health problems like uncontrolled infections, serious heart disease, or poorly managed diabetes.
- You have not had another cancer or a tongue tumor in the last 5 years.
- You are willing to sign a consent form and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help treat advanced mouth cancer. It aims to shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
This trial tests adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy before surgery for advanced laryngeal or hypopharyngeal cancer. The goal is to see if this combination shrinks tumors more and improves outcomes for patients who need their entire voice box removed.
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) given before surgery to treat mouth or throat cancer that has come back. The goal is to shrink the tumor and improve surgery outcomes.
Hear when a new Tongue Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.